# A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

> **NCT01096199** · PHASE1 · TERMINATED · sponsor: **National University Hospital, Singapore** · enrollment: 35 (—)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** TS-ONE, Cisplatin, RAD001

## Key facts

- **NCT ID:** NCT01096199
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** 2012-09
- **Final completion:** —
- **Target enrollment:** 35 (—)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096199, "A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01096199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*